79 results about "Blood cancers" patented technology

A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.

The present invention relates to the use of a compound of formula 3 or a salt thereof for preparing a medicament or a phototherapeutic agent for the treatment of the following diseases, including: acne; AIDS; viral hepatitis; diabetic retinopathy; atypical pneumonia virus infection; coronary Arterial stenosis; carotid artery stenosis; intermittent claudication; Asian (chicken) avian influenza virus infection; cervical dysplasia or various cancers including: blood cancer, cervical cancer, nasopharyngeal cancer, tracheal cancer, laryngeal cancer, bronchial cancer , bronchiolar cancer, bladder cancer, esophagus cancer, stomach cancer, rectal cancer, colon cancer, prostate cancer, hollow organ cancer, bile duct cancer, urinary duct cancer, kidney cancer, uterine cancer, vaginal cancer and other gynecological adnexal cancers. The present invention also relates to methods of treating the above diseases. The present invention further relates to the use of a compound of formula 3 or a salt thereof for the preparation of a photodiagnostic agent for the detection of the above-mentioned diseases and diseases including: atherosclerosis, multiple sclerosis, diabetes, arthritis, rheumatism Arthritis, fungal infection, viral infection, chlamydia infection, bacterial infection, or parasitic infection, HIV infection, hepatitis, herpes simplex, shingles, psoriasis, cardiovascular disease and skin disease. The present invention also relates to methods of detecting the above diseases using photodiagnostic agents. The present invention further relates to a method of cryogenically sterilizing a surgical device or other device, comprising the steps of: providing a compound of formula 3 or a salt thereof on the device; subjecting the device to radiation treatment or sonication. The present invention further relates to a compound of formula 3 or a salt thereof linked or attached to a magnetic element. This compound acts as an MRI enhancer. The present invention also relates to the use of such MRI enhancers for performing MRI scans.

The invention relates to tetrahydroindazolone or tetrahydroindazolone-substituted indazole derivatives with right general formula (I) or (II) and pharmaceutically acceptable salt thereof. The compounds and the pharmaceutically acceptable salt thereof are characterized by inhibiting growth of tumor cells and malignant cells. The tumor cells comprise cancer cells such as breast cancer, lung cancer, cervical carcinoma, rectum cancer, prostatic cancer, liver cancer, blood cancer and the like, thus the tetrahydroindazolone or tetrahydroindazolone-substituted indazole derivatives and the salt thereof can be used for preparing drugs for preventing and treating the breast cancer, the lung cancer, the cervical carcinoma, the rectum cancer, the prostatic cancer, the liver cancer and the blood cancer.

The invention provides a new medicament for treating leukemia, which is prepared from 39 raw material drugs, such as taxus chinensis (tree bark), tender catchweed bedstraw herb, prismatomeria tetrandra, isatis indigotica fort, tuber fleeceflower stem, Yunnan fringed iris herb, fructus corni, hemlock parsley, turtle shell and the like, wherein the taxus chinensis (tree bark) contains 'taxol' which is the top anti-cancer medicament in the world, can be combined with trace of albumin, so that the albumin is accelerated to be aggregated, mitosis of cancer cells can be inhibited, and proliferation of the cancer cells can be effectively stopped. The medicament also comprises the tender catchweed bedstraw herb, suncured ginseng, prismatomeria tetrandra, isatis indigotica fort, tuber fleeceflower stem, Yunnan fringed iris herb, fructus corni, hemlock parsley and turtle shell, so that growth and development of the cancer cells can be controlled, the cancer resistance of a human body can be reinforced, the circulation and metabolic function of the human body can be improved, virus accumulated in the human body is removed outside the body through urine and defecation to achieve the function of preventing cancer. The medicament adopts the Chinese medicaments capable of nourishing yin and supplementing kidney, supplying vital energy, nourishing and activating blood, tonifying qi and controlling blood, softening hardness to dissipate stagnation, removing toxicity and tonifying middle-Jiao and coordinating drug actions of a prescription, administration is increased or reduced according to the course development and classification of the leukemia to achieve the best treatment effect. 38 leukemia cases are treated non-selectively in clinical application, and the total effective rate is over 90 percent.

The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.

The invention relates to anti-leukemia effects of a neurokinin receptor antagonist SR140333, and relates specifically to methods of treating leukemia and relieving leukemia symptoms for subjects, to a method of inhibiting a proliferation of leukemia cells, to uses of the neurokinin receptor antagonist in drugs, medicaments or pharmaceutical compositions utilized for treating leukemia and relieving leukemia symptoms, or inhibiting a proliferation of leukemia cells, and to a pharmaceutical product comprising a neurokinin receptor antagonist as an active ingredient and a specification of the pharmaceutical product.

The invention belongs to the technical field of medicine, and particularly relates to optical isomers represented by the formula (II) and the formula (III) and used as tyrosine kinase inhibitors, and pharmaceutically acceptable salts thereof. The invention also relates to preparation methods of the optical isomers, pharmaceutical preparations containing the optical isomers, and the optical isomers playing important roles in preparation of drugs for prevention and / or treatment of B cell related leukemia (such as B cell chronic lymphocytic cancer, non-hodgkin lymphoma and the like), inflammatory and autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus and the like).

The invention provides a tetracyclic anthraquinone with selective absorption and selective displacement, which is suitable for diseases that can be effectively treated by all tetracyclic anthraquinones, comprising but not limited to intestinal cancer, liver cancer, gastric cancer, breast cancer, lung cancer, ovarian cancer, prostate cancer, glioma, lymph cancer, skin cancer, melanoma, thyroid cancer, multiple myeloma and leukaemia.

The invention provides a total-nutrient formula food or specific total-nutrient formula food or non-total-nutrient formula food for being eaten by a leukemia patient. The total-nutrient formula food is formed by crushing and mixing multiple medicine and food dual-purpose traditional Chinese medicine extract essences extracted by using a pre-hydrolyzed SBE technology and multiple microencapsulated probiotics as well as oligopeptide, prebiotics, amino acid, carbohydrate, multivitamin and mineral extracted by biological enzymolysis in combination with the physical characteristics of the leukemia patient according to the requirements of the General Rules for Special Medical Use Formula Food. The leukemia total-nutrient formula food has the benefit that the leukemia total-nutrient formula food only can be taken as a single source of nutrients to meet the nutritional demands of the leukemia patient, but also can have the efficacies of removing stasis, tonifying qi and enriching the blood, clearing away heat and detoxifying, promoting blood circulation to remove blood stasis, promoting the circulation of qi and removing stasis, cooling blood and stopping bleeding, and nourishing yin.

The present invention relates to a medicine for curing cancers, including 13 Chinese medicinal materials of glaucescent fissistigma root, bushy sophora, root, semiaquilegia tuber, zedoary, prunella spike, pig's bile and others. It is good in therapeutic effect, has no toxic side effect, can eliminate toxic side effect produced in radiotherapy and chemotherapy, and can raise immunity of body, except for blood cancer it can be used for curing all the cancers.

The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.

The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and / or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and / or inhibit the transcription of disease-related genes in the patient (or in a biological sample).